Arbutus Biopharma Corporation (ABUS)
| Market Cap | 407.55M |
| Revenue (ttm) | 8.35M |
| Net Income (ttm) | -84.19M |
| Shares Out | 96.87M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,042,364 |
| Open | 4.05 |
| Previous Close | 4.11 |
| Day's Range | 3.87 - 4.09 |
| 52-Week Range | 2.43 - 5.87 |
| Beta | 2.68 |
| Analysts | Buy |
| Price Target | 6.00 (+48.9%) |
| Est. Earnings Date | Nov 4, 2021 |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-83...
Financial Performance
In 2020, ABUS's revenue was $6.91 million, an increase of 15.02% compared to the previous year's $6.01 million. Losses were -$63.75 million, -58.53% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 48.88% from the latest price.
News
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Arbutus to Participate in October Investor Conferences
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercial...
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializ...
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC™
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializi...
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Propriet...
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatit...
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:ABUS).
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729,...
WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have entere...
Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination...
MENDHAM, N.J. and WARMINSTER, Pa., June 29, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a cli...
Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepati...
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL Internationa...
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver ...
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV...
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chroni...
Arbutus Biopharma Stocks Is Trading Higher On Pan-Coronavirus Research Pact
Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS...